Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM7P3IZ)

Drug Name
3-aminobenzamide Drug Info
Synonyms
3-Aminobenzamide; 3544-24-9; m-Aminobenzamide; Benzamide, 3-amino-; 3-Amino-benzamide; Benzamide, m-amino-; meta-aminobenzamide; 3-ABA; 3-Aminobenzimide; 3-amino benzamide; aniline-3-carboxamide; 3-aminobenzoic acid amide; UNII-8J365YF1YH; CCRIS 3925; EINECS 222-586-9; NSC 36962; BRN 2802373; PARP Inhibitor I, 3-ABA; 3-H2NC6H4CONH2; CHEMBL81977; 3-AB; 8J365YF1YH; CHEBI:64042; GSCPDZHWVNUUFI-UHFFFAOYSA-N; MFCD00007989; 3-Aminobenzamide, 98%; SR-01000075657; HSDB 7581; 3-azanylbenzamide; m-amino benzamide; 4pml; 3-Aminobenzaminde
Cross-matching ID
PubChem CID
1645
ChEBI ID
CHEMBL81977
CAS Number
CAS 3544-24-9
TTD Drug ID
D0K2PD

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.42 0.00e+0 34/36 (94.44%) RPA2;FEN1;POLA2;...
Cell cycle 2.23 0.00e+0 110/124 (88.71%) CDC20;PLK1;CCNA2;...
Spliceosome 2.13 0.00e+0 101/150 (67.33%) LSM5;FUS;SNRPB;...
Mismatch repair 2.00 5.57e-3 22/23 (95.65%) MSH6;RPA2;RFC2;...
Oocyte meiosis 1.98 4.46e-3 90/129 (69.77%) CDC20;PLK1;CCNB2;...
Ribosome biogenesis in eukaryotes 1.92 3.71e-3 52/108 (48.15%) NVL;NOP56;HEATR1;...
Base excision repair 1.88 7.43e-3 29/33 (87.88%) FEN1;PCNA;HMGB1;...
Pyrimidine metabolism 1.83 8.35e-3 40/56 (71.43%) DPYD;RRM2;RRM1;...
Fanconi anemia pathway 1.83 7.43e-3 36/54 (66.67%) RPA2;BLM;USP1;...
Progesterone-mediated oocyte maturation 1.77 1.56e-2 75/100 (75%) PLK1;CCNA2;CCNB2;...
RNA transport 1.72 2.77e-2 128/186 (68.82%) TACC3;FUS;NUP50;...
Homologous recombination 1.71 2.66e-2 35/41 (85.37%) RPA2;BLM;RAD54B;...
mRNA surveillance pathway 1.69 2.74e-2 71/98 (72.45%) FUS;PPP2R1B;SRRM1;...
Nucleotide excision repair 1.66 3.34e-2 40/47 (85.11%) RPA2;RAD23B;RFC2;...
PPAR signaling pathway -1.65 2.88e-2 66/74 (89.19%) PPARG;NR1H3;CYP7A1;...
Sphingolipid metabolism -1.65 2.69e-2 32/49 (65.31%) GLB1;KDSR;SGPP1;...
Alzheimer disease -1.66 2.70e-2 279/369 (75.61%) PSMD8;KIF5A;PSEN1;...
Epithelial cell signaling in Helicobacter pylori infect... -1.66 2.80e-2 62/70 (88.57%) MAPK9;PTPN11;ATP6V0E2;...
Ascorbate and aldarate metabolism -1.68 2.26e-2 15/30 (50%) UGT2B15;UGT2B17;UGT2A3;...
Non-alcoholic fatty liver disease -1.69 2.35e-2 126/155 (81.29%) NDUFA10;NDUFA4;GSK3B;...
Metabolism of xenobiotics by cytochrome P450 -1.69 2.20e-2 49/77 (63.64%) SULT2A1;CYP2C9;ADH1B;...
Porphyrin and chlorophyll metabolism -1.71 1.82e-2 23/43 (53.49%) UGT2B17;HCCS;UGT2A3;...
Protein processing in endoplasmic reticulum -1.71 1.91e-2 127/171 (74.27%) SIL1;MAPK9;BAG2;...
Taurine and hypotaurine metabolism -1.72 1.71e-2 8/11 (72.73%) GGT1;CDO1;CSAD;...
Graft-versus-host disease -1.73 1.68e-2 32/42 (76.19%) HLA-G;IL6;KLRD1;...
Pathways of neurodegeneration -1.73 1.58e-2 354/475 (74.53%) CYC1;NEFH;UBC;...
Rheumatoid arthritis -1.74 1.53e-2 78/93 (83.87%) IL6;TEK;ATP6V0E2;...
Protein digestion and absorption -1.75 1.48e-2 78/103 (75.73%) COL4A6;COL2A1;COL5A2;...
Valine, leucine and isoleucine degradation -1.76 1.27e-2 42/48 (87.5%) ACADS;PCCB;BCAT1;...
Pentose and glucuronate interconversions -1.77 1.28e-2 17/34 (50%) UGT2B15;UGT2B17;UGT2A3;...
Synthesis and degradation of ketone bodies -1.78 1.20e-2 9/10 (90%) BDH2;ACAT2;HMGCS2;...
Glycine, serine and threonine metabolism -1.78 1.20e-2 31/40 (77.5%) BPGM;ALDH7A1;MAOA;...
Steroid hormone biosynthesis -1.78 1.30e-2 43/61 (70.49%) CYP3A4;UGT2B17;UGT2A3;...
Phagosome -1.83 7.63e-3 118/152 (77.63%) RAB5A;HLA-G;DYNC2H1;...
Butanoate metabolism -1.83 8.39e-3 23/28 (82.14%) BDH2;ABAT;AACS;...
Antigen processing and presentation -1.86 6.66e-3 60/78 (76.92%) TAPBP;HLA-G;PSME2;...
Steroid biosynthesis -1.91 1.50e-3 19/20 (95%) LIPA;NSDHL;SQLE;...
Collecting duct acid secretion -1.93 0.00e+0 22/27 (81.48%) ATP6V0E2;ATP6V0A1;ATP6V1F;...
Ferroptosis -1.94 0.00e+0 36/41 (87.8%) PRNP;ACSL6;ACSL5;...
Type I diabetes mellitus -2.02 0.00e+0 38/43 (88.37%) HLA-E;HLA-C;HLA-DOB;...
Lysosome -2.10 0.00e+0 115/128 (89.84%) ABCB9;SLC17A5;SORT1;...
Mineral absorption -2.12 0.00e+0 48/60 (80%) VDR;MT1X;SLC39A4;...
Synaptic vesicle cycle -2.18 0.00e+0 63/78 (80.77%) DNM3;ATP6V0E2;ATP6V0A1;...
Oxidative phosphorylation -2.34 0.00e+0 93/133 (69.92%) NDUFA10;ATP5F1E;NDUFA4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-673 CVCL_0080 Homo sapiens 40uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.002uM - 40uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CL-34 CVCL_1123 Homo sapiens 40uM 6H
HT-29 CVCL_0320 Homo sapiens 0.01uM - 40uM 6H, 24H
LoVo CVCL_0399 Homo sapiens 40uM 6H
MDST8 CVCL_1400 Homo sapiens 40uM 6H
NCI-H508 CVCL_1561 Homo sapiens 40uM 6H
SNU-1040 CVCL_5001 Homo sapiens 40uM 6H
SNU-C4 CVCL_5008 Homo sapiens 40uM 6H
SNU-C5 CVCL_5009 Homo sapiens 40uM 6H
SW480 CVCL_0546 Homo sapiens 40uM 6H
SW620 CVCL_0547 Homo sapiens 40uM 6H
SW948 CVCL_0550 Homo sapiens 40uM 6H
Colorectal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCT 116 CVCL_0291 Homo sapiens 40uM 6H
HT115 CVCL_1294 Homo sapiens 40uM 6H
RKO CVCL_0504 Homo sapiens 40uM 6H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 40uM 6H
SNG-M CVCL_1707 Homo sapiens 40uM 6H
Endometrial carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHUEM-2 CVCL_1327 Homo sapiens 40uM 6H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 40uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 40uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.002uM - 40uM 6H, 24H
DV-90 CVCL_1184 Homo sapiens 40uM 6H
SK-LU-1 CVCL_0624 Homo sapiens 40uM 6H
Lung adenosquamous carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H596 CVCL_1571 Homo sapiens 40uM 6H
Lung large cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COR-L23 CVCL_1133 Homo sapiens 40uM 6H
T3M-10 CVCL_1729 Homo sapiens 40uM 6H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC15 CVCL_1253 Homo sapiens 40uM 6H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1299 CVCL_0060 Homo sapiens 40uM 6H
HCC515 CVCL_5134 Homo sapiens 40uM 6H, 24H
NCI-H2073 CVCL_1523 Homo sapiens 40uM 6H
Small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H1694 CVCL_1495 Homo sapiens 40uM 6H
NCI-H1836 CVCL_1502 Homo sapiens 40uM 6H
Lymph node
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
WSU-DLCL2 CVCL_1787 Homo sapiens 40uM 6H
Ovary
Ovarian carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
EFO-27 CVCL_1194 Homo sapiens 40uM 6H
OV7 CVCL_1623 Homo sapiens 40uM 6H
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
RMG-I CVCL_1663 Homo sapiens 40uM 6H
Ovarian mucinous cystadenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
COV644 CVCL_2011 Homo sapiens 40uM 6H
RMUG-S CVCL_1666 Homo sapiens 40uM 6H
Ovarian undifferentiated carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
TYK-nu CVCL_1774 Homo sapiens 40uM 6H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 40uM 6H
Acute myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NOMO-1 CVCL_1609 Homo sapiens 40uM 6H
PL-21 CVCL_2161 Homo sapiens 40uM 6H
SKM-1 CVCL_0010 Homo sapiens 40uM 6H
Pleural effusion
Histiocytic lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-937 CVCL_0007 Homo sapiens 40uM 6H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 40uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 40uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 40uM 6H, 24H
SK-MEL-1 CVCL_0523 Homo sapiens 40uM 6H
SK-MEL-28 CVCL_0526 Homo sapiens 40uM 6H
Stomach
Gastric adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
AGS CVCL_0139 Homo sapiens 40uM 6H